Labcorp to Scale Digital Pathology Platform Nationwide

Lab services company Labcorp is expanding its collaboration with PathAI to deploy its AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations.

Boston-based PathAI was founded in 2016 to address the need for technology applied to pathology to reduce error rates, increase accuracy and reproducibility.

Labcorp said that the cloud-based technology allows pathologists to view and manage slides digitally and use AI to support key steps in the diagnostic process.

The expansion builds on Labcorp's 2019 investment in PathAI, a collaboration that has since advanced to include AI-driven clinical trial support and validation of novel AI pathology solutions.

Labcorp said deploying AISight Dx would enable fully digital workflows for case management, slide review, collaboration and annotation. The platform also integrates AI-powered image analysis, secure storage and system connectivity to deliver faster turnaround, greater efficiency, reliable quality and improved collaboration.

Labcorp will also incorporate digital pathology workflows in support of its precision medicine products.


"Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration and innovation in pathology," said Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp, in a statement. "PathAI's technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers."
 
AISight Dx is FDA-cleared for primary diagnosis in the US and CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.